版本:
中国

BRIEF-Cellectar Biosciences announces new positive data from phase 1 clinical study of CLR 131 in multiple myeloma

Sept 29 Cellectar Biosciences Inc :

* Cellectar Biosciences announces new positive data from phase 1 clinical study of CLR 131 in multiple myeloma

* Study's data monitoring committee approved patient enrollment to third cohort, which will include a 33 percent dose increase

* All evaluable study participants have achieved stable disease and progression-free survival

* Patients in Cohort 2 did not experience proportional increase in adverse events Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐